Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

As the incidence of Type 2 diabetes has reached near epidemic proportions, the quest for novel therapies to combat this disorder has intensified dramatically. In recent years, the peroxisome proliferator-activated receptor (PPAR) family has received tremendous attention as perhaps an ideal target cl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Expert opinion on investigational drugs 2003-09, Vol.12 (9), p.1489-1500
Hauptverfasser:	Miller, Anne R, Etgen, Garret J
Format:	Artikel
Sprache:	eng
Schlagworte:	diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Humans Ligands Metabolic Syndrome - drug therapy Metabolic Syndrome - metabolism PPAR Receptors, Cytoplasmic and Nuclear - agonists Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors syndrome X Transcription Factors - agonists Transcription Factors - antagonists & inhibitors Transcription Factors - pharmacology TZD
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	As the incidence of Type 2 diabetes has reached near epidemic proportions, the quest for novel therapies to combat this disorder has intensified dramatically. In recent years, the peroxisome proliferator-activated receptor (PPAR) family has received tremendous attention as perhaps an ideal target class to address the multiple metabolic anomalies associated with the diabetic state. This review focuses on a variety of novel PPAR approaches currently being investigated for Type 2 diabetes or the metabolic syndrome, including the highly potent selective PPAR agonists, PPAR combination agonists and alternative PPAR ligands.
ISSN:	1354-3784 1744-7658
DOI:	10.1517/13543784.12.9.1489